PIVALOYL-SUBSTITUTED 2-PYRROLONES INDUCE DEATH OF GASTROINTESTINAL STROMAL TUMORS RESISTANT TO IMATINIB AND CHEMOTHERAPY DRUGS

ORIGINAL ARTICLES. B. EXPERIMENTAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-1-135-140

Published 01.01.2017

Aygul Galembikova⁺⁻
Sergey Boychuk⁺⁻
Svetlana Zykova⁺⁻
Ramil Khusnutdinov⁺⁻
Pavel Dunaev⁺⁻

Aygul Galembikova

Kazan State Medical University

Sergey Boychuk

Kazan State Medical University

Svetlana Zykova

Perm State Pharmaceutical Academy

Ramil Khusnutdinov

Kazan State Medical University

Pavel Dunaev

Kazan State Medical University

##article.numberofdownloads## 72

##article.numberofviews## 81

PDF (Русский)

Keywords

GASTROINTESTINAL STROMAL TUMORS
PIVALOYL-CONTAINING HETEROCYCLIC PYRROLES
APOPTOSIS
CHEMOTHERAPEUTIC DRUGS

How to Cite

Galembikova, A., Boychuk, S., Zykova, S., Khusnutdinov, R., & Dunaev, P. (2017). PIVALOYL-SUBSTITUTED 2-PYRROLONES INDUCE DEATH OF GASTROINTESTINAL STROMAL TUMORS RESISTANT TO IMATINIB AND CHEMOTHERAPY DRUGS. Voprosy Onkologii, 63(1), 135–140. https://doi.org/10.37469/0507-3758-2017-63-1-135-140

Abstract

There are presented data illustrating sensitivity of gastrointestinal stromal tumors (GISTs) to certain chemotherapeutic agents (topoisomerase type II inhibitors, taxanes, vinca alkaloids) and pivaloyl-containing heterocyclic pyrroles (PCHPs). The chemotherapeutic drugs indicated above provided the cytotoxicity to IM-sensitive GIST cells. PCHPs were effective in both IM-sensitive, and resistant GISTs as well. Moreover PCHPs were also active against GISTs harboring the resistance to the chemotherapeutic agents indicated above. PCHPs-treated tumor cells underwent apoptosis due to the M-phase abnormalities and mitotic catastrophe.

https://doi.org/10.37469/0507-3758-2017-63-1-135-140

##article.numberofdownloads## 72

##article.numberofviews## 81

PDF (Русский)

References

Бойчук С.В., Галембикова А.Р., Зыкова С.С., Хуснутдинов Р.Р. Нарушения регуляции клеточного цикла и репарации повреждений ДНК в опухолевых клетках под действием замещенного этилового эфира 2-амино-1Н-пиррол-3-карбоновой кислоты // Современные проблемы науки и образования. - 2015. - № 5. - С. 116.

Бойчук С.В., Галембикова А.Р., Рамазанов Б.Р., Дусинг А. Иматиниб повышает чувствительность клеток гастроинтестинальных стромальных опухолей к ингибиторам топоизомераз II типа // Успехи молекулярной онкологии. - 2015. - № 1. - С. 76-81.

Галембикова А.Р., Дунаев П.Д., Бойчук С.В. Оценка чувствительности гастроинтестинальных стромальных опухолей (ГИСТ) к химиопрепаратам различных групп // Современные проблемы науки и образования. - 2015. - № 6. - С. 255.

Мазуренко Н.Н., Цыганова И.В. Молекулярно-генетические особенности и маркеры гастроинтестинальных стромальных опухолей // Успехи молекулярной онкологии. - 2015. - № 2. - С. 29-40.

Boichuk S., Galembikova A., Zykova S, Ramazanov B. et al. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro // Anti-Cancer Drugs. - 2016. - Vol. 27(7). - P. 620-634.

Boichuk S., Lee D.J., Mehalek KR, Makielski KR, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors // Cancer Res. - 2014. -Vol. 74. - P. 1200-1213.

Demetri, G. D., M. von Mehren, C. D. Blanke, A. D. Van den Abele, B., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors // The New Engl. J. Med. - 2002. - Vol. 347. - P. 472-480.

Gonzalez I., Andreu E.J., Panizo A., Fontalba A. et al. Ima-tinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apopto-sis // Clin. Cancer Res. - 2004. - Vol.10. - P. 751-761.

Gramza A.W., Corless C.L., Heinrich M.C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors // Clin Cancer Res. - 2009. - Vol.15. - P. 7510-7518.

Hirota S., K. Isozaki, Moriyama Y, Hashimoto K. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors // Science (New York, N.Y). - 1998. - Vol. 279. - P. 577-580.

Hopkins TG, Marples M, Stark D. Sunitinib in the management of gastrointestinal stromal tumours (GISTs) // Eur J Surg Oncol. - 2008. - Vol. 34 (8). - P. 844-850.

Maurel J., Martins A.S., Poveda A., Löpez-Guerrero J.A. et al. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for research on sarcomas // Cancer. - 2010. -Vol. 116. - P. 3692-3701.

Pessetto Z.Y Weir S.J., Sethi G., Broward M.A. et al. Drug repurposing for gastrointestinal stromal tumor // Mol Cancer Ther. - 2013. - Vol. 12(7). - P. 1299-1309.

Pessetto, Z. Y., Ma Y., Hirst J. J., von Mehren M. et al. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. // Mol. Cancer Ther. - 2014. - Vol. 13. - P. 2276-2287.

Verweij J., Casali PG., Zalcberg J., LeCesne A. et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial // Lancet. - 2004. - Vol. 364. - P. 1127-1132.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.